MX2007010524A - Formas cristalinas y amorfas del clorhidrato 4-ciano-n-{(2r)-2-[4- (2,3-dihidro-benzo[1-4]dioxin-5-il)-piperazin-1-il]-propil}-n- piridin-2-il-benzamida. - Google Patents

Formas cristalinas y amorfas del clorhidrato 4-ciano-n-{(2r)-2-[4- (2,3-dihidro-benzo[1-4]dioxin-5-il)-piperazin-1-il]-propil}-n- piridin-2-il-benzamida.

Info

Publication number
MX2007010524A
MX2007010524A MX2007010524A MX2007010524A MX2007010524A MX 2007010524 A MX2007010524 A MX 2007010524A MX 2007010524 A MX2007010524 A MX 2007010524A MX 2007010524 A MX2007010524 A MX 2007010524A MX 2007010524 A MX2007010524 A MX 2007010524A
Authority
MX
Mexico
Prior art keywords
dioxin
piperazin
pyridin
benzo
dihydro
Prior art date
Application number
MX2007010524A
Other languages
English (en)
Inventor
Michel Bernatchez
Eric N C Browne
Mark Lankau
Abdolsamad Tadayon
Anthony F Hadfield
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2007010524A publication Critical patent/MX2007010524A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a formas cristalinas y amorfas del receptor antagonista 5-HT1A del clorhidrato 4-ciano-N-{(2R)-2-[4-(2,3-dihidro-benzo[1-4]dioxin-5-il)- piperazin -1-il]-propil}-N-piridin-2-il-benzamida, asi como tambien a las composiciones de los mismos y los metodos para usar dichas composiciones.
MX2007010524A 2005-03-01 2006-02-27 Formas cristalinas y amorfas del clorhidrato 4-ciano-n-{(2r)-2-[4- (2,3-dihidro-benzo[1-4]dioxin-5-il)-piperazin-1-il]-propil}-n- piridin-2-il-benzamida. MX2007010524A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65757505P 2005-03-01 2005-03-01
PCT/US2006/006802 WO2006093853A1 (en) 2005-03-01 2006-02-27 Crystalline and amorphous 4-cyano-n{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride

Publications (1)

Publication Number Publication Date
MX2007010524A true MX2007010524A (es) 2008-01-16

Family

ID=36659970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007010524A MX2007010524A (es) 2005-03-01 2006-02-27 Formas cristalinas y amorfas del clorhidrato 4-ciano-n-{(2r)-2-[4- (2,3-dihidro-benzo[1-4]dioxin-5-il)-piperazin-1-il]-propil}-n- piridin-2-il-benzamida.

Country Status (19)

Country Link
US (2) US20070027162A1 (es)
EP (1) EP1853593A1 (es)
JP (1) JP2008531694A (es)
KR (1) KR20070112797A (es)
CN (1) CN101137648A (es)
AR (1) AR053152A1 (es)
AU (1) AU2006218845A1 (es)
BR (1) BRPI0609370A2 (es)
CA (1) CA2599588A1 (es)
CR (1) CR9319A (es)
GT (1) GT200600098A (es)
IL (1) IL185267A0 (es)
MX (1) MX2007010524A (es)
NI (1) NI200700217A (es)
NO (1) NO20074254L (es)
PE (1) PE20061344A1 (es)
RU (1) RU2007131044A (es)
TW (1) TW200700413A (es)
WO (1) WO2006093853A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600403A (es) * 2005-09-09 2007-09-19 Composiciones y formas de dosificacion farmaceuticas

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645681B2 (en) * 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5568992A (en) * 1995-05-19 1996-10-29 Caterpillar Paving Products Inc. Screed control system for an asphalt paver and method of use
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6287839B1 (en) * 1997-11-19 2001-09-11 Genencor International, Inc. Cellulase producing actinomycetes, cellulase produced therefrom and method of producing same
US6127062A (en) * 1998-03-24 2000-10-03 Duracell Inc End cap seal assembly for an electrochemical cell
TR200100698T2 (tr) * 1998-09-10 2001-07-23 F.Hoffmann-La Roche Ag 5-HT4 alıcı-Antagonistleri olarak Dihidrobenzodioksin Karboksamit ve Keton türevleri
IT1318394B1 (it) * 2000-03-17 2003-08-25 Enichem Spa Processo per la preparazione di 1-esene.
US6469007B2 (en) * 2000-11-28 2002-10-22 Wyeth Serotonergic agents
RU2315762C2 (ru) * 2002-03-12 2008-01-27 Уайт Способ синтеза хиральных n-арилпиперазинов
US7091349B2 (en) * 2002-03-12 2006-08-15 Wyeth Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution
ES2283762T3 (es) * 2002-03-12 2007-11-01 Wyeth Preparacion de acido n1-(2'-piridil)-1,2-propanodiaminosulfamico y su uso en la sintesis de piperazinas biologicamente activas.
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US20050209245A1 (en) * 2004-03-19 2005-09-22 Wyeth Process for preparing N-aryl-piperazine derivatives
TWI257220B (en) * 2005-03-25 2006-06-21 Ind Tech Res Inst Cross-layer rate adaptation mechanism for WLAN

Also Published As

Publication number Publication date
CR9319A (es) 2008-01-21
US20090192311A1 (en) 2009-07-30
AR053152A1 (es) 2007-04-25
RU2007131044A (ru) 2009-04-10
CN101137648A (zh) 2008-03-05
US20070027162A1 (en) 2007-02-01
KR20070112797A (ko) 2007-11-27
EP1853593A1 (en) 2007-11-14
CA2599588A1 (en) 2006-09-08
JP2008531694A (ja) 2008-08-14
WO2006093853A1 (en) 2006-09-08
TW200700413A (en) 2007-01-01
GT200600098A (es) 2006-11-09
IL185267A0 (en) 2008-02-09
AU2006218845A1 (en) 2006-09-08
PE20061344A1 (es) 2007-01-03
NO20074254L (no) 2007-09-24
BRPI0609370A2 (pt) 2010-03-30
NI200700217A (es) 2008-07-24

Similar Documents

Publication Publication Date Title
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
DE602006007556D1 (de) Heteroarylsulfonylstilbene als 5-ht2a-antagonisten
MX2007011848A (es) Antagonistas del receptor de procineticina i.
MY136959A (en) Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
TW200716566A (en) Prokineticin 2 receptor antagonists
TW200637550A (en) Thiazole-4-carboxamide derivatives as mGluR5 antagonists
PE20091035A1 (es) Derivados de 2-aminopirimidina
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
WO2003028641A3 (en) Mch receptor antagonists
ATE393147T1 (de) Kondensierte cycloheptan- und kondensierte azacycloheptan-derivate und ihre verwendung als integrin-rezeptor-antagonisten
NO20073678L (no) Nye fremgangsmater for fremstilling av benzofuran
DE602005009977D1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
DE602005027870D1 (de) Cgrp-rezeptorantagonisten
ATE452130T1 (de) 1-(hetero)aryl-3-aminopyrrolidinderivate zur verwendung als antagonisten des mglur3-rezeptors
DE602006020450D1 (de) Ykinin-rezeptorantagonisten
PL1893589T3 (pl) PODSTAWIONE POCHODNE N-BENZO[D]IZOKSAZOL-3-ILOAMINY JAKO INHIBITORY RECEPTORÓW mGluR5, SEROTONINY (5-HT) I NORADRENALINY I ICH ZASTOSOWANIE DO WYTWARZANIA ŚRODKÓW LECZNICZYCH
ATE450503T1 (de) Pyrrolidinderivate als histamin-h3- rezeptorantagonisten
MX2007010524A (es) Formas cristalinas y amorfas del clorhidrato 4-ciano-n-{(2r)-2-[4- (2,3-dihidro-benzo[1-4]dioxin-5-il)-piperazin-1-il]-propil}-n- piridin-2-il-benzamida.
CR8613A (es) Proceso para preparar derivados de n-aril-piperazina
NO20081100L (no) Farmasoytiske doseringsformer og sammensetninger
MXPA05006587A (es) Compuestos de tiazol como derivados de antagonistas del receptor de la integrina.